For Immediate Release
Chicago, IL – October 26, 2009 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Amazon.com (AMZN), Zimmer Holdings Inc. (ZMH), Stryker Corporation (SYK), Wright Medical (WMGI) and Smith & Nephew (SNN).
Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513
Here are highlights from Friday’s AnalystBlog:
Amazon Generating Solid Growth
Amazon.com’s (AMZN) third quarter earnings beat the Zacks consensus by 12 cents. Revenue beat by 8.3%.
Revenue for the period was $5.5 billion, up 17.2% sequentially and 27.8% year over year. Revenue exceeded the top end of management’s guidance range of $4.75-5.25 billion (up 2.1% sequentially and up 12.9% year over year).
Approximately 52% of sales were generated in North America, which increased 16.0% sequentially and 23.5% year over year. The balance came from the International segment, which increased 18.5% sequentially and 32.8% year over year.
Zimmer Outdoes, Reaffirms Outlook
Zimmer Holdings Inc. (ZMH) today reported earnings per share of 88 cents in the third quarter of 2009, beating the Zacks Consensus Estimate of 86 cents. However, earnings per share declined by 9.3% year over year in the reported quarter.
Net sales in the reported quarter increased 2.4% year over year to $976 million. Excluding an unfavorable foreign currency translation (FX), net sales increased 3.6% year over year. On a geographic basis, U.S. sales represented approximately 60% of total revenues and increased 4% year over year. Europe revenues declined 3% year over year to $242 million. Asia-Pacific contributed $149 million of revenues and increased 8% year over year.
Zimmer has reaffirmed its sales and earnings guidance for full fiscal 2009. For the year, excluding FX, net sales are estimated to increase between 1% and 3% over that in 2008. At the current level, FX is estimated to negatively impact revenue growth by roughly 1.6%. Earnings per share should be in the range of $3.85 to $4.00. Zimmer is a global leader in the design, development, manufacture, and marketing of reconstructive implants, and trauma and related orthopedic surgical products. The company competes in the orthopedic market with players such as Stryker Corporation (SYK), Wright Medical (WMGI) and Smith & Nephew (SNN).
Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=5515.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks “Profit from the Pros” e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=5517
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it’s your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=5518.
Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
Contact:
Mark Vickery
Web Content Editor
312-265-9380
Visit: www.zacks.com
